Cefuroxime sodium (Cefuroxime sodium salt)
(Synonyms: 头孢呋辛钠) 目录号 : GC32086
A cephalosporin antibiotic
Cas No.:56238-63-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Cefuroxime is a cephalosporin antibiotic with broad-spectrum activity against Gram-positive and Gram-negative bacteria including S. pyogenes, S. pneumoniae, S. viridans, E. coli, P. mirabilis, H. influenzae, and N. gonorrhoeae (mean MICs = 0.005-8.2 μg/ml).1 Like other cephalosporins, cefuroxime inhibits peptidoglycan crosslinking and bacterial cell wall synthesis.2 It is resistant to hydrolysis by bacterial β-lactamases, increasing its efficacy against β-lactamase producing Gram-negative bacteria.3 Cefuroxime is protective against Gram-positive and Gram-negative infections in vivo with mean ED50 values ranging from 2 to 35 and 1 to 55 mg/kg, in mice and rats, respectively.4 Formulations containing cefuroxime have been used to treat urinary tract infections.5
1.O'Callaghan, C.H., Sykes, R.B., Griffiths, A., et al.Cefuroxime, a new cephalosporin antibiotic: Activity in vitroAntimicrob. Agents Chemother.9(3)511-519(1976) 2.Curtis, N.A.C., Hughes, J.M., and Ross, G.W.Inhibition of peptidoglycan cross-linking in growing cells of Escherichia coli by penicillins and cephalosporins, and its prevention by R factor-mediated beta-lactamaseAntimicrob. Agents Chemother.9(2)208-213(1976) 3.Richmond, M.H., and Wotton, S.Comparative study of seven cephalosporins: Susceptibility to beta-lactamases and ability to penetrate the surface layers of Escherichia coliAntimicrob. Agents Chemother.10(2)219-222(1976) 4.Ryan, D.M., O'Callaghan, C.H., and Muggleton, P.W.Cefuroxime, a new cephalosporin antibiotic: Activity in vivoAntimicrob. Agents Chemother.9(3)520-525(1976) 5.Masika, W.G., O'Meara, W.P., Holland, T.L., et al.Contribution of urinary tract infection to the burden of febrile illnesses in young children in rural KenyaPLoS One12(3)e0174199(2017)
| Cas No. | 56238-63-2 | SDF | |
| 别名 | 头孢呋辛钠 | ||
| Canonical SMILES | O=C(C(N12)=C(COC(N)=O)CS[C@]2([H])[C@H](NC(/C(C3=CC=CO3)=N\OC)=O)C1=O)[O-].[Na+] | ||
| 分子式 | C16H15N4NaO8S | 分子量 | 446.37 |
| 溶解度 | DMSO : 32 mg/mL (71.69 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2403 mL | 11.2015 mL | 22.4029 mL |
| 5 mM | 0.4481 mL | 2.2403 mL | 4.4806 mL |
| 10 mM | 0.224 mL | 1.1201 mL | 2.2403 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Long-term stability of cefuroxime and cefazolin sodium in intravenous infusions
J Clin Pharm Ther 1996 Jun;21(3):185-9.PMID:8873853DOI:10.1111/j.1365-2710.1996.tb00020.x.
Cefazolin and Cefuroxime sodium are often used as antibiotic infusions for hospitalized patients. Because advance preparation of these intravenous solutions is efficient, the stability of both antibiotics stored at 4 degrees C in polyvinyl chloride (PVC) bags was studied. Five bags of solutions containing either 1 g of cefazolin sodium or 1.5 g of Cefuroxime sodium per 100 ml of 5% dextrose were studied for 1 month by high-performance liquid chromatography (HPLC), visual inspection and pH measurement. No colour change or precipitation was observed. The pH values of both drugs increased significantly over the period of study. Based on a shelf-life of 90% residual potency, the Cefuroxime sodium concentration was stable for 13 days when stored at 4 degrees C, and the cefazolin sodium concentration was stable for at least 30 days at 4 degrees C. Within these limits, both antibiotics may be prepared in advance by a centralized intravenous admixture service.
Stability of Cefuroxime sodium in some aqueous buffered solutions and intravenous admixtures
J Clin Hosp Pharm 1986 Feb;11(1):47-54.PMID:3958213DOI:10.1111/j.1365-2710.1986.tb00827.x.
Cefuroxime sodium (Zinacef) is a new semisynthetic, broad spectrum cephalosporin antibiotic for parenteral administration which is stable to most of the beta-lactamases. The stability of Cefuroxime sodium in aqueous solutions, with or without phosphate buffer, and in 5% dextrose and 0.9% sodium chloride injections was studied using a stability-indicating high-pressure liquid chromatographic method developed in our laboratory. The optimum pH range of stability was determined to be approximately 4.5-7.3. Both buffered and unbuffered solutions followed first-order decomposition. In 5% dextrose and 0.9% sodium chloride injections, cefuroxime was stable for 1 day (more than 90% potent) at 25 degrees C and for at least 30 days at 5 degrees C. At -10 degrees C, there was negligible decomposition after 30 days. The pH values of the solutions stored at 5 degrees C and -10 degrees C remained in the maximum stability range and the solutions were clear even after 30 days of storage. Thawing the frozen solutions in a microwave oven adversely affected the stability.
Stability of ceftazidime (with arginine) and of Cefuroxime sodium in infusion-pump reservoirs
Am J Hosp Pharm 1992 Nov;49(11):2761-4.PMID:1471642doi
The stability of ceftazidime (with arginine) and Cefuroxime sodium was studied after storage in infusion-pump reservoirs at freezing and refrigerated temperatures and subsequent simulated administration over 24 hours at near-body temperature. Polyvinyl chloride reservoirs and glass vials were filled with ceftazidime (with arginine) or Cefuroxime sodium at various concentrations, diluted in sterile water. Three reservoirs each of ceftazidime 30 and 60 mg/mL and of cefuroxime 22.5, 30, 45, and 60 mg/mL were stored for various times and at various temperatures. Three glass vials each of ceftazidime or cefuroxime 30 and 60 mg/mL were stored for 30 days at -20 degrees C, followed by 4 days at 3 degrees C and 24 hours at 30 degrees C. Samples obtained periodically during storage and during simulated administration were analyzed with high-performance liquid chromatography. Both drugs maintained at least 90% of their initial concentration under all of the test conditions except simulated administration at 30 degrees C, during which degradation accelerated. In portable infusion-pump reservoirs, ceftazidime 30 and 60 mg/mL and cefuroxime 30 and 60 mg/mL were stable for 30 days at -20 degrees C followed by 4 days at 3 degrees C; ceftazidime 30 and 60 mg/mL was stable for 10 days at 3 degrees C; and cefuroxime 22.5 and 45 mg/mL was stable for 7 days at 3 degrees C. However, the drugs may need to be administered over less than 24 hours when the pump reservoir is worn on the patient's body.
Macular toxicity of low-concentration cefuroxime during cataract surgery in vitrectomized eyes
Ophthalmic Res 2022 Aug 15.PMID:35970172DOI:10.1159/000526449.
Objective: The objective of this study was to determine the toxic effect and clinical characteristics of 1 mg/ml Cefuroxime sodium on retinas after phacoemulsification in vitrectomized eyes. Methods: Cataract patients with vitrectomized eyes were studied retrospectively. Phacoemulsification combined with intraocular lens implantation was performed uneventfully. Best Corrected Visual Acuity（BCVA＿ intraocular pressure（IOP＿ fundus photography, macular central thickness, and angiography were collected and analyzed. They were studied in patients with macular edema to evaluate macular toxicity. Results: 92 cases (92 eyes) were enrolled, including 44 eyes of males and 48 eyes of females with an average age of 55.35 ± 12.32 years. Univariate analysis showed that the intraoperative use of balanced salt solution (BSS) containing 1 mg/ml Cefuroxime sodium compound electrolyte and macular involvement in primary vitrectomy were important risk factors for macular edema on the first day after cataract surgery (P < 0.05). In addition, the characteristics of this kind of macular edema were studied; the thickness of macular fovea was significantly high at 1-day follow-up (P < 0.05), but there was no difference between pre-operation and 1-week post-operation (P > 0.05). Conclusion: Low-concentration Cefuroxime sodium can cause acute macular edema in vitrectomized eyes, which can heal within one week after surgery.
Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and Cefuroxime sodium in partial-fill glass bottles
Drug Intell Clin Pharm 1988 Jan;22(1):54-7.PMID:3349921DOI:10.1177/106002808802200113.
The stability and compatibility of clindamycin phosphate admixed with four beta-lactams, an experimental monobactam (aztreonam), and three cephalosporins (cefoperazone sodium, cefonicid sodium, and Cefuroxime sodium), were studied. Aztreonam alone and the combination of clindamycin phosphate-aztreonam were prepared in duplicate polypropylene syringes. Each cephalosporin antibiotic as well as the three clindamycin phosphate-cephalosporin combinations were admixed in duplicate 100 ml partial-fill glass bottles containing either dextrose 5% in water or NaCl 0.9%. All solutions were examined, antibiotic concentrations were determined, and pH was measured at the time of admixture and 1, 4, 8, 12, 24, and 48 hours later. The solutions were maintained at room temperature under fluorescent lighting for the length of the study. Antibiotic concentrations were determined by drug-specific high performance liquid chromatographic assays. Significant instability or incompatibility was defined as a decrease in concentration of greater than ten percent relative to the initial concentration measured at the time of admixture. All antibiotics were stable for 48 hours. In the combination studies, clindamycin was stable for 48 hours, both in partial-fill glass bottles and syringes. Aztreonam, cefoperazone, cefonicid, and cefuroxime were also stable for 48 hours.